Tags

Type your tag names separated by a space and hit enter

NOP Ligands for the Treatment of Anxiety and Mood Disorders.
Handb Exp Pharmacol. 2019; 254:233-257.HE

Abstract

Many studies point toward the nociceptin/orphanin FQ (N/OFQ) and the N/OFQ peptide receptor (NOP) as targets for the development of innovative drugs for treating anxiety- and mood-related disorders. Evidence supports the view that the activation of NOP receptors with agonists elicits anxiolytic-like effects, while its blockade with NOP antagonists promotes antidepressant-like actions in rodents. Genetic studies showed that NOP receptor knockout mice display an antidepressant-like phenotype, and NOP antagonists are inactive in these animals. In contrast, the genetic blockade of NOP receptor signaling generally displays an increase of anxiety states in the elevated plus-maze test. In this chapter we summarized the most relevant findings of NOP receptor ligands in the modulation of anxiety and mood disorders, and the putative mechanisms of action are discussed.

Authors+Show Affiliations

Behavioral Pharmacology Laboratory, Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal, Brazil. egavioli@hotmail.com.Behavioral Pharmacology Laboratory, Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal, Brazil.Department of Medical Sciences, Section of Pharmacology, and National Institute of Neuroscience, University of Ferrara, Ferrara, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30535941

Citation

Gavioli, Elaine C., et al. "NOP Ligands for the Treatment of Anxiety and Mood Disorders." Handbook of Experimental Pharmacology, vol. 254, 2019, pp. 233-257.
Gavioli EC, Holanda VAD, Ruzza C. NOP Ligands for the Treatment of Anxiety and Mood Disorders. Handb Exp Pharmacol. 2019;254:233-257.
Gavioli, E. C., Holanda, V. A. D., & Ruzza, C. (2019). NOP Ligands for the Treatment of Anxiety and Mood Disorders. Handbook of Experimental Pharmacology, 254, 233-257. https://doi.org/10.1007/164_2018_188
Gavioli EC, Holanda VAD, Ruzza C. NOP Ligands for the Treatment of Anxiety and Mood Disorders. Handb Exp Pharmacol. 2019;254:233-257. PubMed PMID: 30535941.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - NOP Ligands for the Treatment of Anxiety and Mood Disorders. AU - Gavioli,Elaine C, AU - Holanda,Victor A D, AU - Ruzza,Chiara, PY - 2018/12/12/pubmed PY - 2019/7/28/medline PY - 2018/12/12/entrez KW - Animal behavior KW - Anxiety KW - Depression KW - NOP receptor KW - Nociceptin/orphanin FQ KW - Stress SP - 233 EP - 257 JF - Handbook of experimental pharmacology JO - Handb Exp Pharmacol VL - 254 N2 - Many studies point toward the nociceptin/orphanin FQ (N/OFQ) and the N/OFQ peptide receptor (NOP) as targets for the development of innovative drugs for treating anxiety- and mood-related disorders. Evidence supports the view that the activation of NOP receptors with agonists elicits anxiolytic-like effects, while its blockade with NOP antagonists promotes antidepressant-like actions in rodents. Genetic studies showed that NOP receptor knockout mice display an antidepressant-like phenotype, and NOP antagonists are inactive in these animals. In contrast, the genetic blockade of NOP receptor signaling generally displays an increase of anxiety states in the elevated plus-maze test. In this chapter we summarized the most relevant findings of NOP receptor ligands in the modulation of anxiety and mood disorders, and the putative mechanisms of action are discussed. SN - 0171-2004 UR - https://www.unboundmedicine.com/medline/citation/30535941/NOP_Ligands_for_the_Treatment_of_Anxiety_and_Mood_Disorders_ L2 - https://dx.doi.org/10.1007/164_2018_188 DB - PRIME DP - Unbound Medicine ER -